Los Angeles Capital Management LLC bought a new stake in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Get Rating) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 59,630 shares of the biotechnology company's stock, valued at approximately $1,608,000. Los Angeles Capital Management LLC owned 0.23% of Arcturus Therapeutics at the end of the most recent reporting period.
A number of other large investors also recently made changes to their positions in the business. DekaBank Deutsche Girozentrale increased its holdings in shares of Arcturus Therapeutics by 2.6% in the 4th quarter. DekaBank Deutsche Girozentrale now owns 23,700 shares of the biotechnology company's stock valued at $920,000 after purchasing an additional 600 shares during the period. Allspring Global Investments Holdings LLC acquired a new position in Arcturus Therapeutics in the fourth quarter worth approximately $32,000. Byrne Asset Management LLC increased its holdings in Arcturus Therapeutics by 29.4% in the first quarter. Byrne Asset Management LLC now owns 4,000 shares of the biotechnology company's stock worth $108,000 after buying an additional 910 shares during the last quarter. Daiwa Securities Group Inc. increased its holdings in Arcturus Therapeutics by 44.0% in the first quarter. Daiwa Securities Group Inc. now owns 3,503 shares of the biotechnology company's stock worth $94,000 after buying an additional 1,071 shares during the last quarter. Finally, Formidable Asset Management LLC increased its holdings in Arcturus Therapeutics by 8.5% in the first quarter. Formidable Asset Management LLC now owns 14,050 shares of the biotechnology company's stock worth $379,000 after buying an additional 1,100 shares during the last quarter. Institutional investors and hedge funds own 80.10% of the company's stock.Get Arcturus Therapeutics alerts:
Arcturus Therapeutics Price Performance
ARCT opened at $17.48 on Thursday. Arcturus Therapeutics Holdings Inc. has a 1-year low of $11.70 and a 1-year high of $58.45. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.05 and a quick ratio of 3.05. The business has a 50 day moving average of $17.09 and a 200-day moving average of $20.70.Arcturus Therapeutics (NASDAQ:ARCT – Get Rating) last posted its quarterly earnings data on Tuesday, August 9th. The biotechnology company reported ($0.82) earnings per share for the quarter, beating the consensus estimate of ($1.90) by $1.08. Arcturus Therapeutics had a negative return on equity of 73.87% and a negative net margin of 407.91%. During the same period in the previous year, the business earned ($2.07) earnings per share. On average, equities analysts expect that Arcturus Therapeutics Holdings Inc. will post -6.71 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of research firms recently commented on ARCT. Cantor Fitzgerald restated an "overweight" rating on shares of Arcturus Therapeutics in a report on Monday, May 9th. Guggenheim dropped their price objective on Arcturus Therapeutics from $83.00 to $36.00 in a report on Wednesday, May 11th. Barclays dropped their price objective on Arcturus Therapeutics from $17.00 to $16.00 and set an "underweight" rating on the stock in a report on Wednesday. Citigroup downgraded Arcturus Therapeutics from a "buy" rating to a "neutral" rating and lowered their price target for the company from $86.00 to $29.00 in a report on Thursday, April 21st. Finally, The Goldman Sachs Group lowered their price target on Arcturus Therapeutics from $14.00 to $8.00 and set a "sell" rating on the stock in a report on Tuesday, May 24th. Four analysts have rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $38.75.
Arcturus Therapeutics Profile
Arcturus Therapeutics Holdings Inc, an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU.
- Get a free copy of the StockNews.com research report on Arcturus Therapeutics (ARCT)
- Large And Small Oil-And-Gas Stocks See Post-Earnings Bounce
- The 2 Dow Stocks with Decade-Long Win Streaks on the Line
- Could Rite Aid Be an Acquisition Target, Again?
- The How And Why of Investing in Oil Stocks
- The How and Why of Investing in Gold Stocks
Want to see what other hedge funds are holding ARCT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Get Rating).
Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.